Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 219

1.

Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer.

Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM.

Cancer Discov. 2015 May;5(5):520-33. doi: 10.1158/2159-8290.CD-14-1101. Epub 2015 Mar 3.

PMID:
25735774
2.

Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2.

Holloway KR, Sinha VC, Toneff MJ, Bu W, Hilsenbeck SG, Li Y.

PLoS One. 2015 Jan 30;10(1):e0117239. doi: 10.1371/journal.pone.0117239. eCollection 2015.

3.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-Rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV.

Breast Cancer Res. 2015 Jan 9;17(1):3. doi: 10.1186/s13058-014-0508-5.

4.

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18261-6. doi: 10.1073/pnas.1421415111. Epub 2014 Dec 8.

PMID:
25489091
5.

The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.

Karlin KL, Mondal G, Hartman JK, Tyagi S, Kurley SJ, Bland CS, Hsu TY, Renwick A, Fang JE, Migliaccio I, Callaway C, Nair A, Dominguez-Vidana R, Nguyen DX, Osborne CK, Schiff R, Yu-Lee LY, Jung SY, Edwards DP, Hilsenbeck SG, Rosen JM, Zhang XH, Shaw CA, Couch FJ, Westbrook TF.

Cell Rep. 2014 Nov 20;9(4):1318-32. doi: 10.1016/j.celrep.2014.10.011. Epub 2014 Nov 6.

6.

A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.

Niravath P, Tham YL, Wang T, Rodriguez A, Foreman C, Hilsenbeck SG, Elledge R, Rimawi M.

Oncologist. 2015 Jan;20(1):13. doi: 10.1634/theoncologist.2014-0278. Epub 2014 Nov 6.

7.

Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.

Scollon S, Bergstrom K, Kerstein RA, Wang T, Hilsenbeck SG, Ramamurthy U, Gibbs RA, Eng CM, Chintagumpala MM, Berg SL, McCullough LB, McGuire AL, Plon SE, Parsons DW.

Genome Med. 2014 Sep 17;6(9):69. doi: 10.1186/s13073-014-0069-3. eCollection 2014.

8.

AACR Cancer Progress Report 2014.

Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ.

Clin Cancer Res. 2014 Oct 1;20(19 Suppl):S1-S112. doi: 10.1158/1078-0432.CCR-14-2123. Epub 2014 Sep 16. No abstract available.

PMID:
25228531
9.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.

10.

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH.

Clin Cancer Res. 2015 Apr 1;21(7):1688-98. doi: 10.1158/1078-0432.CCR-14-0432. Epub 2014 Sep 10.

PMID:
25208879
11.

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.

Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS.

Nat Commun. 2014 Aug 7;5:4577. doi: 10.1038/ncomms5577.

12.

STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer.

Wei W, Tweardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM, Lewis MT.

Stem Cells. 2014 Oct;32(10):2571-82. doi: 10.1002/stem.1752.

PMID:
24891218
13.

An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW.

Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.

14.

Pediatric data sharing in genomic research: attitudes and preferences of parents.

Burstein MD, Robinson JO, Hilsenbeck SG, McGuire AL, Lau CC.

Pediatrics. 2014 Apr;133(4):690-7. doi: 10.1542/peds.2013-1592. Epub 2014 Mar 10.

15.

Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis.

Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang P.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1008-13. doi: 10.1073/pnas.1318124111. Epub 2014 Jan 6.

16.

Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy.

Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, Holloway K, Hilsenbeck SG, Huang S, Atkinson R, Woodward W, Jindal S, Borges VF, Gutierrez C, Zhang H, Schedin PJ, Osborne CK, Tweardy DJ, Li Y.

Elife. 2013 Dec 31;2:e00996. doi: 10.7554/eLife.00996.

17.

Participants' recall and understanding of genomic research and large-scale data sharing.

Robinson JO, Slashinski MJ, Wang T, Hilsenbeck SG, McGuire AL.

J Empir Res Hum Res Ethics. 2013 Oct;8(4):42-52. doi: 10.1525/jer.2013.8.4.42.

18.

Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.

Fan Y, Ge N, Wang X, Sun W, Mao R, Bu W, Creighton CJ, Zheng P, Vasudevan S, An L, Yang J, Zhao YJ, Zhang H, Li XN, Rao PH, Leung E, Lu YJ, Gray JW, Schiff R, Hilsenbeck SG, Osborne CK, Yang J, Zhang H.

J Pathol. 2014 Jan;232(1):75-86. doi: 10.1002/path.4283.

19.

Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer.

Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG, Fuqua SA.

Breast Cancer Res Treat. 2013 Sep 28. [Epub ahead of print]

20.

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.

Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC.

Breast Cancer Res. 2013;15(5):R77.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk